ATE354584T1 - Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen - Google Patents

Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Info

Publication number
ATE354584T1
ATE354584T1 AT04029270T AT04029270T ATE354584T1 AT E354584 T1 ATE354584 T1 AT E354584T1 AT 04029270 T AT04029270 T AT 04029270T AT 04029270 T AT04029270 T AT 04029270T AT E354584 T1 ATE354584 T1 AT E354584T1
Authority
AT
Austria
Prior art keywords
solid phase
unprotected
aqueous solutions
chemical ligation
native chemical
Prior art date
Application number
AT04029270T
Other languages
English (en)
Inventor
Lynne Canne
Stephen B H Kent
Reyna Simon
Original Assignee
Gryphon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Therapeutics Inc filed Critical Gryphon Therapeutics Inc
Application granted granted Critical
Publication of ATE354584T1 publication Critical patent/ATE354584T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT04029270T 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen ATE354584T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4955397P 1997-06-13 1997-06-13

Publications (1)

Publication Number Publication Date
ATE354584T1 true ATE354584T1 (de) 2007-03-15

Family

ID=21960431

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04029270T ATE354584T1 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
AT98929035T ATE285415T1 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98929035T ATE285415T1 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Country Status (9)

Country Link
US (4) US6326468B1 (de)
EP (1) EP1001968B1 (de)
JP (1) JP2002505672A (de)
AT (2) ATE354584T1 (de)
AU (1) AU745094B2 (de)
CA (1) CA2292724A1 (de)
DE (2) DE69837170T2 (de)
ES (2) ES2235336T3 (de)
WO (1) WO1998056807A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
DE69837170T2 (de) * 1997-06-13 2007-11-22 Amylin Pharmaceuticals, Inc., San Diego Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
US6844161B2 (en) 1997-09-04 2005-01-18 Gryphon Therapeutics, Inc. Modular protein libraries and methods of preparation
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US7001745B1 (en) * 1998-09-30 2006-02-21 New England Biolabs, Inc. Intein mediated peptide ligation
EP1159289A1 (de) * 1999-03-11 2001-12-05 Gryphon Sciences Chemische synthese und verwendung von löslichen membranproteinrezeptordomänen
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1307214A4 (de) * 2000-08-11 2006-01-18 Invitrogen Corp Hochhomogene molekulare marker für ektrophorese
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US6977292B2 (en) * 2000-09-01 2005-12-20 Gryphon Therapeutics Nucleophile-stable thioester generating compounds, methods of production and use
US7273923B2 (en) * 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
ATE346950T1 (de) * 2001-03-09 2006-12-15 Boston Probes Inc Kombinationsoligomere betreffende verfahren, kits und zusammensetzungen
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
EP2292273A3 (de) 2001-10-10 2011-11-23 BioGeneriX AG Remodellierung und Glycokonjugation von Peptiden
WO2003106615A2 (en) * 2002-06-10 2003-12-24 Geneprot, Inc. Post-cleavage sulfur deprotection for convergent protein synthesis by chemical ligation
ATE312605T1 (de) * 2002-06-29 2005-12-15 Aquanova Ger Solubilisate Tech Isoflavonkonzentrate sowie verfahren zu ihrer herstellung
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
WO2004053460A2 (en) * 2002-12-11 2004-06-24 New England Biolabs, Inc. Carrier-ligand fusions and uses thereof
US8034900B2 (en) * 2002-12-30 2011-10-11 Amylin Pharmaceuticals, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
SI1624891T2 (sl) * 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
WO2004105685A2 (en) * 2003-05-22 2004-12-09 Gryphon Therapeutics, Inc. Displaceable linker solid phase chemical ligation
US7414028B1 (en) 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
JP4895826B2 (ja) 2004-02-20 2012-03-14 バイオサーフェス エンジニアリング テクノロジーズ,インク. 骨形成蛋白−2の正のモジュレーター
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
EP1749022A2 (de) * 2004-05-24 2007-02-07 Rigel Pharmaceuticals, Inc. Verfahren zur cyclisierung von synthetischen polymeren
KR20080003849A (ko) 2005-03-31 2008-01-08 아밀린 파마슈티칼스, 인크. 비만 및 섭식 장애의 조절, 예방 및 치료를 위한 조성물 및방법
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US7674881B2 (en) * 2005-10-07 2010-03-09 The University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
US20090118271A1 (en) * 2005-10-19 2009-05-07 Chugai Seiyaku Kabushiki Kaisha Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
CA2692240C (en) 2006-06-22 2018-03-13 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
EP2120985B1 (de) 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 Peptide zur Verwendung bei der Behandlung Psychotischer- und Angsterkrankungen
WO2009032133A2 (en) * 2007-08-28 2009-03-12 Ipsen Pharma S.A.S. Methods and intermediates for chemical synthesis of polypeptides and proteins
EP2536287A4 (de) * 2010-02-18 2015-10-07 Advanced Proteome Therapeutics Inc Ortsspezifische modifikation von proteinen durch chemische modifikation zur bildung von proteinkonjugaten, proteindimerbildung und stapelpeptide
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
FR2981352B1 (fr) * 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
US9545449B2 (en) 2012-05-11 2017-01-17 Advanced Proteone Therapeutics Inc. Site-specific labeling and targeted delivery of proteins for the treatment of cancer
WO2013177231A1 (en) 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
US11273176B2 (en) 2016-03-02 2022-03-15 The Brigham And Women's Hospital, Inc. Use of PLA2G5-deficient suppressive macrophages in suppression of inflammation
EP3590951A4 (de) * 2017-03-02 2021-01-06 Glytech, Inc. Herstellungsverfahren für aminosäurepolymer
KR20210072021A (ko) 2018-10-01 2021-06-16 유니베르시떼 드 제네브 생물학 분석에 적합한 복수의 폴리펩티드 변이체의 생산 방법
KR102769851B1 (ko) * 2018-11-30 2025-02-20 가부시키가이샤 도우사 고가쿠 겐큐쇼 펩티드 티오에스테르 및 펩티드의 신규 제조 방법
AU2020361681A1 (en) 2019-10-10 2022-05-05 1859, Inc. Methods and systems for microfluidic screening
US20210230218A1 (en) * 2019-10-23 2021-07-29 Mabplex International, Ltd. Oligopeptide linker intermediate and preparation method thereof
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064940A (en) * 1988-05-11 1991-11-12 Protein Technologies, Inc. Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
DK0832096T3 (da) * 1995-05-04 2001-10-01 Scripps Research Inst Syntese af proteiner ved nativ kemisk ligering
JP4358307B2 (ja) * 1996-12-24 2009-11-04 ザ スクリップス リサーチ インスティテュート 一般的化学結合
DE69837170T2 (de) * 1997-06-13 2007-11-22 Amylin Pharmaceuticals, Inc., San Diego Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
US6329468B1 (en) * 2000-01-21 2001-12-11 Bostik Findley, Inc. Hot melt adhesive based on semicrystalline flexible polyolefins

Also Published As

Publication number Publication date
DE69837170T2 (de) 2007-11-22
DE69837170D1 (de) 2007-04-05
ATE285415T1 (de) 2005-01-15
AU8069598A (en) 1998-12-30
ES2235336T3 (es) 2005-07-01
WO1998056807A1 (en) 1998-12-17
US20020132975A1 (en) 2002-09-19
US7094871B2 (en) 2006-08-22
AU745094B2 (en) 2002-03-14
US20050209440A1 (en) 2005-09-22
DE69828287D1 (de) 2005-01-27
CA2292724A1 (en) 1998-12-17
EP1001968A1 (de) 2000-05-24
US20020169282A1 (en) 2002-11-14
JP2002505672A (ja) 2002-02-19
ES2282788T3 (es) 2007-10-16
EP1001968B1 (de) 2004-12-22
US6326468B1 (en) 2001-12-04
DE69828287T2 (de) 2005-12-15
US7030217B2 (en) 2006-04-18

Similar Documents

Publication Publication Date Title
DE69828287D1 (de) Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
Dongré et al. Influence of peptide composition, gas-phase basicity, and chemical modification on fragmentation efficiency: evidence for the mobile proton model
Han et al. Ion trap collisional activation of c and z• ions formed via gas-phase ion/ion electron transfer dissociation
NO993341L (no) Analoger av paratyroidhormon
EA200000190A1 (ru) Водные аэрозольные препараты, содержащие биологически активные макромолекулы, и способ получения соответствующих аэрозолей
GB9822692D0 (en) Chemical ionization source for mass spectrometry
ATE214419T1 (de) Heisshärtende wäschefeste rohbau-versiegelung
WO2003057845A3 (en) Automated systems and methods for analysis of protein post-translational modification
DE69732250D1 (de) Zyklische peptide mit breitspektrum antimikrobieller aktivität
DK0881906T4 (da) Farmaceutisk sammensætning til immunmodulation, som er baseret på peptider og adjuvanser
CA2163426A1 (en) Method and apparatus for desorption and ionization of analytes
ATE197307T1 (de) Neuroaktive peptide
GB2308227A8 (en) Electrospray and atmospheric pressure chemical ionization mass spectrometer and ion source
Leymarie et al. Tandem mass spectrometry for structural characterization of proline-rich proteins: application to salivary PRP-3
AU4052389A (en) Derivatized glass supports for peptide and protein sequencing
NO995891L (no) LH-RH peptidanaloger, anvendelser og farmasoeytiske blandinger inneholdende disse
EP1983059A3 (de) Reaktionsgemische zur Herstellung von Dipeptiden
Kidwell et al. Sequencing of peptides by secondary ion mass spectrometry
AU8812498A (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
GB0113657D0 (en) Improved native chemical ligation with three or more components
GB9816514D0 (en) Novel method
AUPR378001A0 (en) Protein chip
WO1999020760A3 (en) Herg family potassium ion channel genes and protein
WO2002037121A3 (en) Detection of modified amino acids by mass spectrometry
AU2002322506A1 (en) Non-affinity based isotope tagged peptides and methods for using the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties